Want to see ATXI full AI Analyst Report?
Top Page
Avenue Therapeutics
(OTC:ATXI)
Select Model
Select Model
Rating:48Neutral
Price Target:
$0.54
▼(-7.07% Downside)
Action:Reiterated
Date:08/28/26
The score is held down primarily by weak financial performance (zero TTM revenue, ongoing losses, and continued cash burn alongside shrinking equity). Technicals provide partial offset with a strong uptrend above major moving averages, but overbought momentum indicators add near-term risk. Valuation contributes negatively due to the loss-driven negative P/E and lack of dividend support.
Positive Factors
Debt-free balance sheet
The absence of debt reduces interest and refinancing pressure while preserving financial flexibility. A debt-free structure gives Avenue more room to pursue development priorities and withstand operating volatility, although its limited equity base still constrains resilience.
Negative Factors
No current revenue
The absence of trailing revenue indicates that Avenue currently lacks a recurring commercial revenue base to fund operations. This leaves future performance dependent on advancing drug programs, approvals, partnerships, or other monetization events rather than established product demand.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
The absence of debt reduces interest and refinancing pressure while preserving financial flexibility. A debt-free structure gives Avenue more room to pursue development priorities and withstand operating volatility, although its limited equity base still constrains resilience.
Read all positive factors
Avenue Therapeutics (ATXI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.79M
Dividend YieldN/A
Average Volume (3M)5.45K
Price to Earnings (P/E)―
Beta (1Y)0.87
Revenue Growth-100.00%
EPS Growth72.97%
CountryUS
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,294,967
10 Day Avg. Volume9,369
30 Day Avg. Volume5,449
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)1.16
Price to Sales (P/S)1.52
P/FCF Ratio-1.16
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Avenue Therapeutics Business Overview & Revenue Model
Company Description
Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading produc...
How the Company Makes Money
Avenue Therapeutics’ ability to generate revenue is primarily tied to monetizing its drug-development programs rather than diversified operating businesses. In general, the company can make money through (i) collaboration, licensing, or commercial...
Avenue Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
44
Neutral
Cash Flow
26
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.40M | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -3.06M | -3.29M | -11.70M | 4.05M | -2.44M | 7.00K |
| Net Income | -2.78M | -2.91M | -11.65M | -10.38M | -3.55M | -3.73M |
Balance Sheet | ||||||
| Total Assets | 1.98M | 2.93M | 2.67M | 1.85M | 6.84M | 3.96M |
| Cash, Cash Equivalents and Short-Term Investments | 1.94M | 2.85M | 2.59M | 1.78M | 6.71M | 3.76M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.41M | 1.10M | 816.00K | 1.20M | 3.58M | 509.00K |
| Stockholders Equity | 569.00K | 1.83M | 2.80M | 1.58M | 3.90M | 3.45M |
Cash Flow | ||||||
| Free Cash Flow | -1.38M | -1.83M | -9.03M | -12.45M | -7.60M | -3.75M |
| Operating Cash Flow | -1.38M | -1.83M | -9.03M | -9.45M | -7.60M | -3.75M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -3.00M | 0.00 | 0.00 |
| Financing Cash Flow | 0.00 | 2.09M | 9.84M | 7.53M | 10.54M | 4.38M |
Avenue Therapeutics Technical Analysis
Positive
0.58
Price Trends
0.33
Positive
0.37
Positive
0.41
Positive
Market Momentum
0.07
Negative
66.21
Neutral
91.57
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATXI, the sentiment is Positive. The current price of 0.58 is above the 20-day moving average (MA) of 0.37, above the 50-day MA of 0.33, and above the 200-day MA of 0.41, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 66.21 is Neutral, neither overbought nor oversold. The STOCH value of 91.57 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATXI.
Avenue Therapeutics Risk Analysis
Avenue Therapeutics disclosed 65 risk factors in its most recent earnings report. Avenue Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Avenue Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.79M | -0.64 | -155.23% | ― | -100.00% | 72.97% | |
46 Neutral | $16.13M | -0.28 | -67.15% | ― | ― | 57.48% | |
46 Neutral | $4.05M | -0.50 | -131.35% | ― | -50.79% | -180.59% | |
45 Neutral | $8.87M | -0.17 | -1532.33% | ― | -39.29% | 27.41% | |
43 Neutral | $14.82M | -0.31 | 3398.40% | ― | ― | 15.37% | |
40 Underperform | $8.24M | -0.18 | -329.08% | ― | ― | -19.07% |
* Healthcare Sector Average
ATXI
Avenue Therapeutics
0.54
-0.19
-25.68%
ENSC
Ensysce Biosciences
0.46
-1.65
-78.33%
CTXR
Citius Pharmaceuticals
0.59
-0.63
-51.89%
SKYE
Skye Bioscience
1.86
-31.10
-94.36%
CALC
CalciMedica
2.17
-13.28
-85.95%
ADXN
Addex Therapeutics
3.65
-4.10
-52.90%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.